Akero Therapeutics Inc AKRO:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/10/24 EDT
19.65UNCH (UNCH)
Volume
33,379
Close
19.65UNCH (UNCH)
Volume
534,022
52 week range
11.25 - 58.38
Loading...
  • Open21.35
  • Day High21.45
  • Day Low19.59
  • Prev Close19.65
  • 52 Week High58.38
  • 52 Week High Date06/13/23
  • 52 Week Low11.25
  • 52 Week Low Date10/27/23

Key Stats

  • Market Cap1.359B
  • Shares Out69.15M
  • 10 Day Average Volume0.64M
  • Dividend-
  • Dividend Yield-
  • Beta-0.29
  • YTD % Change-15.85

KEY STATS

  • Open21.35
  • Day High21.45
  • Day Low19.59
  • Prev Close19.65
  • 52 Week High58.38
  • 52 Week High Date06/13/23
  • 52 Week Low11.25
  • 52 Week Low Date10/27/23
  • Market Cap1.359B
  • Shares Out69.15M
  • 10 Day Average Volume0.64M
  • Dividend-
  • Dividend Yield-
  • Beta-0.29
  • YTD % Change-15.85

RATIOS/PROFITABILITY

  • EPS (TTM)-2.85
  • P/E (TTM)-6.89
  • Fwd P/E (NTM)-4.84
  • EBITDA (TTM)-172.841M
  • ROE (TTM)-35.22%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)4.66%

EVENTS

  • Earnings Date08/09/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Akero Therapeutics Inc

 

Profile

MORE
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY...
Mark Iwicki
Independent Chairman of the Board
Andrew Cheng M.D., Ph.D
President, Chief Executive Officer, Director
William White J.D.
Chief Financial Officer, Executive Vice President, Head of Corporate Development, Treasurer
Scott Gangloff
Chief Technology Officer
Address
601 Gateway Boulevard, Suite 350
South San Francisco, CA
94080
United States

Top Peers

SYMBOLLASTCHG%CHG
SYRE
Spyre Therapeutics Inc
36.93UNCHUNCH
BLTE
Belite Bio Inc
42.05UNCHUNCH
FDMT
4D Molecular Therapeutics Inc
25.70UNCHUNCH
SRRK
Scholar Rock Holding Corp
13.35UNCHUNCH
MORF
Morphic Holding Inc
28.62UNCHUNCH